The Vall d’Hebron Institute of Oncology (VHIO), in line with its strategic commitment to advancing cancer care and knowledge across…
en_news
In 2025, European experts advanced practical safeguards for medical AI, strengthening on ethics, legal compliance, clinical usability and secure digital…
The Carlos III Health Institute (ISCIII) has published the final resolution of grant awards corresponding to the 2025 Strategic Action…
The new multi-sector public-private partnership funded by the Innovative Health Initiative (IHI) brings together 18 partners across nine countries, including…
The family of Ozelot, the artistic name of Fernando Valero Casanova, recently visited the Vall d’Hebron Institute of Oncology (VHIO)…
Researchers from the Hospital del Mar Research Institute and the VHIO’s Growth Factors Group have demonstrated, in animal models, the…
The report, published in Nature, reveals that polyamines bind to specific domains in proteins and operate as a metabolic shield…
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
Friend of Manuel Barros Association donates €12,000 to VHIO to advance biliary tract cancer research
On 17 December, Javier García, President of the Friends of Manuel Barros Association, visited the Vall d’Hebron Institute of Oncology…
Published in The New England Journal of Medicine, findings from the investigator-initiated phase 3 CLL17 randomized trial demonstrate that limited…
